Skip to content
Catalyst

OutcomesOutcome

Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score

1 finding from 1 compound ↓reported in points (0-40)

Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score

1 finding · 1 compound · by evidence strength. No dose is advised.

Fig. 2 Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score1 compound outer ring on requestSelected Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score · centre
×1.60
Labels
Measured outcomeInspector

Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score

Findings drawn, by strength

1finding · 1 compound

  • Very limited1
Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

Compound lowersFindingsStrongest
1
Very limited

Not pooled · no summary effect · point at a mark · Tab, then the arrow keys

Reported to move it1 finding

  1. L-theanineMoved: lowersEvidence: Very limitedPaper: PMID 371695152023
    Who
    Adults 18-60 with DSM-5 OCD and baseline Y-BOCS above 21; fluvoxamine given to both arms as background (100 mg daily, 200 mg daily after week 5); 10-week parallel-group trial; primary outcome was Y-BOCS total decrease from baseline; result recorded is the week-10 contrast
    Dose studied
    L-theanine 100 mg twice daily, oral, added to fluvoxamine

    Also, total Y-BOCS scores were lower in L-theanine compared to placebo group at week 5 (P = 0.039, Cohen's d = 0.60) and 10 (P = 0.008, Cohen's d = 0.80).”

    Quoted verbatim from L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.RCT · 2 monthsPermalink

How it is measured

Total score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS; Goodman and colleagues 1989), a clinician-rated semi-structured interview of 10 severity items, five for obsessions and five for compulsions (time occupied, interference, distress, resistance and control), each rated 0 to 4, summed to 0 to 40; higher is worse.

Papers about it

As an endpoint1

Show the paperHide the paper
  • L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.

    Psychiatry and clinical neurosciences2023PMID 37169515Via: named in the paper, as read